Key result
Pharmacological cardioversion with bepridil prior to ablation for persistent AF resulted in an 87% AF-free rate in those restoring sinus rhythm, vs 29% in those who failed and 72% in controls.
Why the study?
Does pharmacological cardioversion with bepridil prior to ablation predict AF-free rates in patients with persistent atrial fibrillation?
Case-Control (n=82)
Does pharmacological cardioversion with bepridil prior to ablation predict AF-free rates in patients with persistent atrial fibrillation?
Successful pharmacological cardioversion with bepridil prior to ablation predicts a significantly higher AF-free rate post-ablation in patients with persistent AF, suggesting its utility in patient selection.
Bepridil response may identify persistent AF patients with higher ablation success; hypothesis-generating and leaves open prospective validation.
AIMS: Bepridil is highly effective in terminating persistent atrial fibrillation (AF). Despite continued treatment, a high rate of AF recurrence after pharmacological cardioversion (PC) with bepridil has been reported. Bepridil therapy is also associated with significant adverse effects. METHODS AND RESULTS: This retrospective case-control study included 82 patients with persistent AF (PEF). Group 1 (22 patients) comprised cases undergoing AF ablation following attempted PC with bepridil. Group 2 (60 patients) comprised control that underwent AF ablation without bepridil pre-treatment. In Group 1, 15 patients (68%) restored sinus rhythm (SR) with bepridil (SR group) and 7 continued to have AF (AF group). SR group underwent extensive pulmonary vein isolation (EPVI) alone. AF group and Group 2 underwent linear ablation after EPVI, if AF was inducible. At the end of 18 +/- 5 months off antiarrhythmic drugs, the AF-free rate was 87% in SR group, 29% in AF group, and 72% in Group 2 (72 vs. 29%, P = 0.02). CONCLUSION: Following AF ablation in patients who successfully restored SR with bepridil pre-treatment, AF-free rate was significantly higher than in those who failed to do so. Conversion to SR with bepridil might help select the optimal patients with PEF for catheter ablation.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (2009) conducted a case-control in persistent atrial fibrillation (n=82). Pharmacological cardioversion with bepridil vs. AF ablation without bepridil pre-treatment was evaluated on AF-free rate off antiarrhythmic drugs (p=0.02). Pharmacological cardioversion with bepridil prior to ablation for persistent AF resulted in an 87% AF-free rate in those restoring sinus rhythm, vs 29% in those who failed and 72% in controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: